NLRP3 and adult-onset Still disease: The safety profile of anakinra has been studied for years, as it is approved for the treatment of autoimmune and inflammatory diseases such as rheumatoid arthritis, juvenile and adult Still's disease, and cryopyrin-associated periodic syndrome (CAPS) [27], [28], [29].